Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

Triple-negative breast cancer (TNBC) is a highly heterogeneous disease, and molecular subtyping may result in improved diagnostic precision and targeted therapies. Our previous study classified TNBCs into four subtypes with putative therapeutic targets. Here, we conducted the FUTURE trial (ClinicalT...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Res
Main Authors: Jiang, Yi-Zhou, Liu, Yin, Xiao, Yi, Hu, Xin, Jiang, Lin, Zuo, Wen-Jia, Ma, Ding, Ding, Jiahan, Zhu, Xiaoyu, Zou, Jianjun, Verschraegen, Claire, Stover, Daniel G., Kaklamani, Virginia, Wang, Zhong-Hua, Shao, Zhi-Ming
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Singapore 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8027015/
https://ncbi.nlm.nih.gov/pubmed/32719455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41422-020-0375-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados